The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: Results of the multi-centre CHAMPS trial

Winfred C. Wang; Carlo Brugnara; Cathie Snyder; Lynn Wynn; Zora Rogers; Karen Kalinyak; Clark Brown; Asif Qureshi; Carolyn Bigelow; Lynne Neumayr; Kim Smith-Whitley; David H K Chui; Mardee Delahunty; Rob Woolson; Martin Steinberg; Marilyn Telen; Karen Kesler

doi:10.1111/j.1365-2141.2010.08523.x

The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: Results of the multi-centre CHAMPS trial

Winfred C. Wang, Carlo Brugnara, Cathie Snyder, Lynn Wynn, Zora Rogers, Karen Kalinyak, Clark Brown, Asif Qureshi, Carolyn Bigelow, Lynne Neumayr, Kim Smith-Whitley, David H K Chui, Mardee Delahunty, Rob Woolson, Martin Steinberg, Marilyn Telen, Karen Kesler

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

In a phase-II multi-centre double-blinded trial, we evaluated haematological effects of oral hydroxycarbamide (HC) and magnesium (Mg) in patients with HbSC, aged 5-53years old. Subjects were randomized to HC+placebo, Mg+placebo, HC+Mg, or placebo+placebo. The primary endpoint was the proportion of hyperdense red blood cells after 8weeks. Thirty-six subjects were evaluable, but the study was terminated early because of slow enrollment. In the combined HC groups, mean cell volume and HbF were increased, but differences were not seen in hyperdense red cells or vaso-occlusive events. Mg had no effects. Further investigation of hydroxycarbamide as monotherapy in HbSC disease is warranted.

Original language	English (US)
Pages (from-to)	771-776
Number of pages	6
Journal	British Journal of Haematology
Volume	152
Issue number	6
DOIs	https://doi.org/10.1111/j.1365-2141.2010.08523.x
State	Published - Mar 2011

Keywords

Hb SC disease
Hydroxycarbamide
Hydroxyurea
Magnesium
Sickle cell

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/j.1365-2141.2010.08523.x

Cite this

Wang, W. C., Brugnara, C., Snyder, C., Wynn, L., Rogers, Z., Kalinyak, K., Brown, C., Qureshi, A., Bigelow, C., Neumayr, L., Smith-Whitley, K., Chui, D. H. K., Delahunty, M., Woolson, R., Steinberg, M., Telen, M., & Kesler, K. (2011). The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: Results of the multi-centre CHAMPS trial. British Journal of Haematology, 152(6), 771-776. https://doi.org/10.1111/j.1365-2141.2010.08523.x

Wang, WC, Brugnara, C, Snyder, C, Wynn, L, Rogers, Z, Kalinyak, K, Brown, C, Qureshi, A, Bigelow, C, Neumayr, L, Smith-Whitley, K, Chui, DHK, Delahunty, M, Woolson, R, Steinberg, M, Telen, M & Kesler, K 2011, 'The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: Results of the multi-centre CHAMPS trial', British Journal of Haematology, vol. 152, no. 6, pp. 771-776. https://doi.org/10.1111/j.1365-2141.2010.08523.x

@article{73f75b9fe5814ef9b93c74d2c5f69695,

title = "The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: Results of the multi-centre CHAMPS trial",

abstract = "In a phase-II multi-centre double-blinded trial, we evaluated haematological effects of oral hydroxycarbamide (HC) and magnesium (Mg) in patients with HbSC, aged 5-53years old. Subjects were randomized to HC+placebo, Mg+placebo, HC+Mg, or placebo+placebo. The primary endpoint was the proportion of hyperdense red blood cells after 8weeks. Thirty-six subjects were evaluable, but the study was terminated early because of slow enrollment. In the combined HC groups, mean cell volume and HbF were increased, but differences were not seen in hyperdense red cells or vaso-occlusive events. Mg had no effects. Further investigation of hydroxycarbamide as monotherapy in HbSC disease is warranted.",

keywords = "Hb SC disease, Hydroxycarbamide, Hydroxyurea, Magnesium, Sickle cell",

author = "Wang, {Winfred C.} and Carlo Brugnara and Cathie Snyder and Lynn Wynn and Zora Rogers and Karen Kalinyak and Clark Brown and Asif Qureshi and Carolyn Bigelow and Lynne Neumayr and Kim Smith-Whitley and Chui, {David H K} and Mardee Delahunty and Rob Woolson and Martin Steinberg and Marilyn Telen and Karen Kesler",

year = "2011",

month = mar,

doi = "10.1111/j.1365-2141.2010.08523.x",

language = "English (US)",

volume = "152",

pages = "771--776",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - The effects of hydroxycarbamide and magnesium on haemoglobin SC disease

T2 - Results of the multi-centre CHAMPS trial

AU - Wang, Winfred C.

AU - Brugnara, Carlo

AU - Snyder, Cathie

AU - Wynn, Lynn

AU - Rogers, Zora

AU - Kalinyak, Karen

AU - Brown, Clark

AU - Qureshi, Asif

AU - Bigelow, Carolyn

AU - Neumayr, Lynne

AU - Smith-Whitley, Kim

AU - Chui, David H K

AU - Delahunty, Mardee

AU - Woolson, Rob

AU - Steinberg, Martin

AU - Telen, Marilyn

AU - Kesler, Karen

PY - 2011/3

Y1 - 2011/3

N2 - In a phase-II multi-centre double-blinded trial, we evaluated haematological effects of oral hydroxycarbamide (HC) and magnesium (Mg) in patients with HbSC, aged 5-53years old. Subjects were randomized to HC+placebo, Mg+placebo, HC+Mg, or placebo+placebo. The primary endpoint was the proportion of hyperdense red blood cells after 8weeks. Thirty-six subjects were evaluable, but the study was terminated early because of slow enrollment. In the combined HC groups, mean cell volume and HbF were increased, but differences were not seen in hyperdense red cells or vaso-occlusive events. Mg had no effects. Further investigation of hydroxycarbamide as monotherapy in HbSC disease is warranted.

AB - In a phase-II multi-centre double-blinded trial, we evaluated haematological effects of oral hydroxycarbamide (HC) and magnesium (Mg) in patients with HbSC, aged 5-53years old. Subjects were randomized to HC+placebo, Mg+placebo, HC+Mg, or placebo+placebo. The primary endpoint was the proportion of hyperdense red blood cells after 8weeks. Thirty-six subjects were evaluable, but the study was terminated early because of slow enrollment. In the combined HC groups, mean cell volume and HbF were increased, but differences were not seen in hyperdense red cells or vaso-occlusive events. Mg had no effects. Further investigation of hydroxycarbamide as monotherapy in HbSC disease is warranted.

KW - Hb SC disease

KW - Hydroxycarbamide

KW - Hydroxyurea

KW - Magnesium

KW - Sickle cell

UR - http://www.scopus.com/inward/record.url?scp=79951982532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951982532&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2010.08523.x

DO - 10.1111/j.1365-2141.2010.08523.x

M3 - Article

C2 - 21275961

AN - SCOPUS:79951982532

SN - 0007-1048

VL - 152

SP - 771

EP - 776

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 6

ER -

The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: Results of the multi-centre CHAMPS trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this